BACK TO ALL REFERENCES
ENDOTARGET: Reducing inflammation and preventing health-to-disease transition in treatment of arthritis
The ENDOTARGET consortium project explores the role of chronic systemic inflammation as a driver in the transition from health to disease. The consortium will study immunologically active compounds derived from intestinal microbiota.
€7 m
in funding
4
years
12
partners
7
countries
Key numbers
About the project
Rheumatic diseases affect more than 40% of Europe's population and cause significant disability, pain, reduced lifespan and a very high economic burden. The ENDOTARGET consortium project, led by Helsinki University Hospital (HUS), aims to explore the relationship between gut microbiota, intestinal permeability and systemic endotoxemia. It also aims to understand their role as drivers of disease onset and disease activity in rheumatoid arthritis, osteoarthritis and spondyloarthritis. The findings of the research consortium may lead to the identification and development of novel preventive and therapeutic approaches.
Impact of the project:
Significant social impact on the lives of patients suffering from rheumatic diseases: the project aims to predict and prevent the health-to-disease transition of individuals.
Funding instrument Horizon Europe
Spinverse’s role
Spinverse experts provided their expertise on the complex funding proposal process, concept development and consortium building to secure the successful outcome of the proposal.
The help of Spinverse was invaluable in the preparation of the grant application. Spinverse helped with creating the budget, with feeding the text into the system and in creating figures and finalizing the text. They truly wanted the application to succeed and worked very hard to achieve this goal..
Supporting the UN Sustainable Development Goals
We share what we learn
Read our latest news on our references
